A top-5 pharmaceutical company sought to understand differentiating features of competitor COVID-19 vaccine programs and forecast regional market scenarios and commercial implications.
A global pharmaceutical giant engaged Shift Health to explore additional RNA virus indications to inform lifecycle management for a promising antiviral in clinical development for COVID-19.
A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.
To support a mid-stage clinical development program, a top-5 pharmaceutical company engaged Shift Health to obtain an understanding of physicians’ decision-making process with alternative therapies.
A player in the medical cannabis space required support to uncover and catalogue scientific evidence that established the link between specific cannabis-based metabolites and their therapeutic benefit.
Recognizing the dynamic nature of the psychiatry therapeutic arena, a top-5 pharmaceutical company required support in characterizing and prioritizing the stakeholder environment to inform how Medical Affairs could work with other functions to optimize patient care.
A leading pharmaceutical company required support in identifying and planning for risks and scenarios that could arise during a multinational Phase 3 vaccine clinical trial.